002317 众生药业
午间休市 07-16 11:30:00
资讯
新帖
简况
股市必读:众生药业(002317)7月15日董秘有最新回复
证券之星 · 01:18
股市必读:众生药业(002317)7月15日董秘有最新回复
半年BD狂飙千亿、龙头预增13倍!创新药涨停潮再起
格隆汇 · 07-15 13:50
半年BD狂飙千亿、龙头预增13倍!创新药涨停潮再起
众生药业:已收首付款20,000万元未确认收入
证券之星 · 07-15 11:37
众生药业:已收首付款20,000万元未确认收入
异动快报:众生药业(002317)7月15日10点44分触及涨停板
证券之星 · 07-15 10:45
异动快报:众生药业(002317)7月15日10点44分触及涨停板
众生药业:公司正积极推进RAY1225注射液及ZSP1601片的III期临床试验
证券之星 · 07-14 20:52
众生药业:公司正积极推进RAY1225注射液及ZSP1601片的III期临床试验
7月13日众生药业涨6.97%,红土创新医疗保健股票A基金重仓该股
证券之星 · 07-13 16:43
7月13日众生药业涨6.97%,红土创新医疗保健股票A基金重仓该股
众生药业涨6.97%,开源证券二个月前给出“买入”评级
证券之星 · 07-13 16:43
众生药业涨6.97%,开源证券二个月前给出“买入”评级
众生药业创60日新高,开源证券二个月前给出“买入”评级
证券之星 · 07-10
众生药业创60日新高,开源证券二个月前给出“买入”评级
异动快报:众生药业(002317)7月10日10点44分触及涨停板
证券之星 · 07-10
异动快报:众生药业(002317)7月10日10点44分触及涨停板
众生药业(002317)披露使用闲置募集资金及自有资金进行现金管理进展公告,7月8日股价下跌3.21%
证券之星 · 07-08
众生药业(002317)披露使用闲置募集资金及自有资金进行现金管理进展公告,7月8日股价下跌3.21%
7月6日众生药业涨5.65%,兴全多维价值混合A基金重仓该股
证券之星 · 07-06
7月6日众生药业涨5.65%,兴全多维价值混合A基金重仓该股
众生药业涨5.65%,开源证券二个月前给出“买入”评级
证券之星 · 07-06
众生药业涨5.65%,开源证券二个月前给出“买入”评级
众生药业涨8.71%,开源证券二个月前给出“买入”评级
证券之星 · 07-01
众生药业涨8.71%,开源证券二个月前给出“买入”评级
异动快报:众生药业(002317)6月29日13点48分触及涨停板
证券之星 · 06-29
异动快报:众生药业(002317)6月29日13点48分触及涨停板
股市必读:众生药业(002317)6月26日董秘有最新回复
证券之星 · 06-29
股市必读:众生药业(002317)6月26日董秘有最新回复
众生药业:公司会充分结合实际,积极使用新技术
证券之星 · 06-26
众生药业:公司会充分结合实际,积极使用新技术
众生药业涨9.99%,开源证券一个月前给出“买入”评级
证券之星 · 06-18
众生药业涨9.99%,开源证券一个月前给出“买入”评级
6月18日众生药业(002317)涨停分析:减肥药、MASH创新药、流感药驱动
证券之星 · 06-18
6月18日众生药业(002317)涨停分析:减肥药、MASH创新药、流感药驱动
众生药业(002317)披露使用闲置自有资金进行委托理财的进展公告,6月17日股价下跌4.71%
证券之星 · 06-17
众生药业(002317)披露使用闲置自有资金进行委托理财的进展公告,6月17日股价下跌4.71%
众生药业:昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药
证券之星 · 06-17
众生药业:昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药
加载更多
公司概况
公司名称:
广东众生药业股份有限公司
所属行业:
医药制造业
上市日期:
2009-12-11
主营业务:
广东众生药业股份有限公司的主营业务是药品研发、生产和销售。公司的主要产品是昂拉地韦片、来瑞特韦片、复方血栓通系列产品、脑栓通胶囊、复方丹参片、众生丸系列产品、清热祛湿颗粒、羧甲司坦口服溶液(片)、盐酸氨溴索口服溶液、头孢克肟分散片、头孢拉定胶囊、异烟肼片、吡嗪酰胺片、盐酸乙胺丁醇片、利福平胶囊、利巴韦林片、硫糖铝口服混悬液、瑞巴派特片、奥美拉唑肠溶胶囊、盐酸氮䓬斯汀滴眼液、普拉洛芬滴眼液、地夸磷索钠滴眼液、环孢素滴眼液(III)、氯雷他定片、富马酸氯马斯汀口服溶液。
发行价格:
55.00
{"stockData":{"symbol":"002317","market":"SZ","secType":"STK","nameCN":"众生药业","latestPrice":32.28,"timestamp":1784174736000,"preClose":33.29,"halted":0,"volume":70096987,"delay":0,"changeRate":-0.0303,"floatShares":762000000,"shares":850000000,"eps":0.3447,"marketStatus":"午间休市","change":-1.01,"latestTime":"07-16 11:30:00","open":32,"high":33.19,"low":29.96,"amount":2185000000,"amplitude":0.097,"askPrice":32.32,"askSize":6,"bidPrice":32.28,"bidSize":248,"shortable":0,"etf":0,"ttmEps":0.3447,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784178000000},"marketStatusCode":3,"adr":0,"adjPreClose":33.29,"symbolType":"stock","openAndCloseTimeList":[[1784165400000,1784172600000],[1784178000000,1784185200000]],"highLimit":36.62,"lowLimit":29.96,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":849930477,"isCdr":false,"pbRate":6.8,"roa":"--","peRate":93.646649,"roe":"2.43%","epsLYR":0.33,"committee":0.818605,"marketValue":27436000000,"turnoverRate":0.092,"status":1,"floatMarketCap":24585000000},"requestUrl":"/m/hq/s/002317","defaultTab":"news","newsList":[{"id":"2651460830","title":"股市必读:众生药业(002317)7月15日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2651460830","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651460830?lang=zh_cn&edition=full","pubTime":"2026-07-16 01:18","pubTimestamp":1784135891,"startTime":"0","endTime":"0","summary":"截至2026年7月15日收盘,众生药业报收于33.29元,上涨6.87%,换手率12.74%,成交量97.01万手,成交额32.03亿元。公司控股子公司众生睿创与齐鲁制药签署《许可协议》,众生睿创授权齐鲁制药在中国地区内对RAY1225注射液进行生产与商业化销售,是公司推动创新药平台建设与后续新药上市商业化的重要举措。当日关注点交易信息汇总:7月15日主力资金净流出1574.1万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600001640.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","002317","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651879434","title":"半年BD狂飙千亿、龙头预增13倍!创新药涨停潮再起","url":"https://stock-news.laohu8.com/highlight/detail?id=2651879434","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651879434?lang=zh_cn&edition=full","pubTime":"2026-07-15 13:50","pubTimestamp":1784094601,"startTime":"0","endTime":"0","summary":"政策密集加码","market":"us","thumbnail":"https://img3.gelonghui.com/9d73a-d7eab21c-e179-4850-9c4c-edf64e1fd8eb.jpg?guru_height=716&guru_width=1280&guru_size=127989","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/9d73a-d7eab21c-e179-4850-9c4c-edf64e1fd8eb.jpg?guru_height=716&guru_width=1280&guru_size=127989"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5584162","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["688192","BD","000566","06978","BK1574","002940","BK0146","IBBQ","BK1161","BK0239","BK0188","BK0216","BK0060","159992","600664","300149","BK0077","BK0028","BK0012","002317","MEDX","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651365764","title":"众生药业:已收首付款20,000万元未确认收入","url":"https://stock-news.laohu8.com/highlight/detail?id=2651365764","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651365764?lang=zh_cn&edition=full","pubTime":"2026-07-15 11:37","pubTimestamp":1784086657,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业07月15日在投资者关系平台上答复投资者关心的问题。公司已收到上述《许可协议》首付款20,000万元,结合RAY1225注射液的研发进度、企业会计准则等相关规定以及协议约定,签订协议时,RAY1225注射液尚未获得上市批准,因此公司未对已收取的首付款确认收入,后续满足收入确认条件后,会依规计入对应的报告期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500019216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","002317","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651355314","title":"异动快报:众生药业(002317)7月15日10点44分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2651355314","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651355314?lang=zh_cn&edition=full","pubTime":"2026-07-15 10:45","pubTimestamp":1784083527,"startTime":"0","endTime":"0","summary":"证券之星7月15日盘中消息,10点44分众生药业(002317)触及涨停板。其所属行业中药目前上涨。领涨股为陇神戎发。该股为减肥药,创新药,化学原料药概念热股,当日减肥药概念上涨5.98%,创新药概念上涨4.94%,化学原料药概念上涨4.25%。7月14日的资金流向数据方面,主力资金净流出6000.32万元,占总成交额2.44%,游资资金净流入4962.77万元,占总成交额2.02%,散户资金净流入1037.54万元,占总成交额0.42%。近5日资金流向一览见下表:众生药业主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500015839.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","002317","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651106306","title":"众生药业:公司正积极推进RAY1225注射液及ZSP1601片的III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2651106306","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651106306?lang=zh_cn&edition=full","pubTime":"2026-07-14 20:52","pubTimestamp":1784033569,"startTime":"0","endTime":"0","summary":"RAY1225注射液是具有全球自主知识产权的创新结构多肽药物,具有GLP-1受体和GIP受体双重激动活性,得益于优异的药代动力学特性,具备每两周注射一次的超长效药物潜力,临床上拟用于2型糖尿病及肥胖/超重等患者的治疗。公司正积极推进RAY1225注射液及ZSP1601片的III期临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400046398.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002317","BK0077","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651301192","title":"7月13日众生药业涨6.97%,红土创新医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651301192","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651301192?lang=zh_cn&edition=full","pubTime":"2026-07-13 16:43","pubTimestamp":1783932211,"startTime":"0","endTime":"0","summary":"证券之星消息,7月13日众生药业涨6.97%创60日新高,收盘报31.6元,换手率11.46%,成交量87.28万手,成交额26.06亿元。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为红土创新基金的红土创新医疗保健股票A。红土创新医疗保健股票A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300023622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","002317","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651192390","title":"众生药业涨6.97%,开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2651192390","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651192390?lang=zh_cn&edition=full","pubTime":"2026-07-13 16:43","pubTimestamp":1783932205,"startTime":"0","endTime":"0","summary":"今日众生药业涨6.97%,收盘报31.6元。2026年4月30日,开源证券研究员余汝意,巢舒然发布了对众生药业的研报《公司信息更新报告:2025年经营业绩稳健提升,创新布局赋能发展》,该研报对众生药业给出“买入”评级。此外,东海证券研究员杜永宏,付婷,华鑫证券研究员胡博新近期也对该股发布了研报,同样给出“买入”评级。众生药业个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300023620.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650428183","title":"众生药业创60日新高,开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2650428183","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650428183?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:29","pubTimestamp":1783672184,"startTime":"0","endTime":"0","summary":"今日众生药业创60日新高,收盘报29.54元。2026年4月30日,开源证券研究员余汝意,巢舒然发布了对众生药业的研报《公司信息更新报告:2025年经营业绩稳健提升,创新布局赋能发展》,该研报对众生药业给出“买入”评级。此外,东海证券研究员杜永宏,付婷,华鑫证券研究员胡博新近期也对该股发布了研报,同样给出“买入”评级。众生药业个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000029049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650906676","title":"异动快报:众生药业(002317)7月10日10点44分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2650906676","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650906676?lang=zh_cn&edition=full","pubTime":"2026-07-10 10:45","pubTimestamp":1783651526,"startTime":"0","endTime":"0","summary":"证券之星7月10日盘中消息,10点44分众生药业(002317)触及涨停板。其所属行业中药目前上涨。领涨股为众生药业。该股为减肥药,创新药,医药概念热股,当日减肥药概念上涨4.69%,创新药概念上涨4.13%,医药概念上涨3.24%。7月9日的资金流向数据方面,主力资金净流入1241.19万元,占总成交额1.17%,游资资金净流出1453.19万元,占总成交额1.37%,散户资金净流入212.0万元,占总成交额0.2%。近5日资金流向一览见下表:众生药业主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000013087.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","002317","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649991217","title":"众生药业(002317)披露使用闲置募集资金及自有资金进行现金管理进展公告,7月8日股价下跌3.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649991217","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649991217?lang=zh_cn&edition=full","pubTime":"2026-07-08 22:10","pubTimestamp":1783519831,"startTime":"0","endTime":"0","summary":"截至2026年7月8日收盘,众生药业报收于25.97元,较前一交易日下跌3.21%,最新总市值为220.73亿元。近日,众生药业发布《关于使用闲置募集资金进行现金管理及闲置自有资金进行委托理财的进展公告》。公告显示,公司于2026年7月8日使用闲置募集资金3,500万元及全资子公司华南药业、先强药业使用闲置自有资金合计6,000万元购买结构性存款产品,产品期限分别为68天、91天和110天,预期年化收益率区间为1.00%至1.75%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800042577.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0239","BK0077","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649642421","title":"7月6日众生药业涨5.65%,兴全多维价值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649642421","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649642421?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:38","pubTimestamp":1783327118,"startTime":"0","endTime":"0","summary":"证券之星消息,7月6日众生药业涨5.65%创60日新高,收盘报28.99元,换手率9.02%,成交量68.69万手,成交额19.71亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共5家,其中持有数量最多的公募基金为兴证全球基金的兴全多维价值混合A。兴全多维价值混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600022247.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0077","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649264240","title":"众生药业涨5.65%,开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2649264240","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649264240?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:38","pubTimestamp":1783327112,"startTime":"0","endTime":"0","summary":"今日众生药业涨5.65%,收盘报28.99元。2026年4月30日,开源证券研究员余汝意,巢舒然发布了对众生药业的研报《公司信息更新报告:2025年经营业绩稳健提升,创新布局赋能发展》,该研报对众生药业给出“买入”评级。此外,东海证券研究员杜永宏,付婷,华鑫证券研究员胡博新近期也对该股发布了研报,同样给出“买入”评级。众生药业个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600022244.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648163125","title":"众生药业涨8.71%,开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2648163125","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648163125?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:46","pubTimestamp":1782895600,"startTime":"0","endTime":"0","summary":"今日众生药业涨8.71%,收盘报26.71元。2026年4月30日,开源证券研究员余汝意,巢舒然发布了对众生药业的研报《公司信息更新报告:2025年经营业绩稳健提升,创新布局赋能发展》,该研报对众生药业给出“买入”评级。此外,东海证券研究员杜永宏,付婷,华鑫证券研究员胡博新近期也对该股发布了研报,同样给出“买入”评级。众生药业个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100031475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647323453","title":"异动快报:众生药业(002317)6月29日13点48分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2647323453","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647323453?lang=zh_cn&edition=full","pubTime":"2026-06-29 13:50","pubTimestamp":1782712243,"startTime":"0","endTime":"0","summary":"证券之星6月29日盘中消息,13点48分众生药业(002317)触及涨停板。其所属行业中药目前上涨。领涨股为太极集团。该股为创新药,减肥药,医药概念热股,当日创新药概念上涨7.17%,减肥药概念上涨7.03%,医药概念上涨5.2%。6月26日的资金流向数据方面,主力资金净流出4680.62万元,占总成交额5.81%,游资资金净流入1461.72万元,占总成交额1.81%,散户资金净流入3218.9万元,占总成交额4.0%。近5日资金流向一览见下表:众生药业主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900016446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","BK0239","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647486513","title":"股市必读:众生药业(002317)6月26日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2647486513","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647486513?lang=zh_cn&edition=full","pubTime":"2026-06-29 01:32","pubTimestamp":1782667933,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘,众生药业报收于22.59元,下跌4.32%,换手率4.59%,成交量34.99万手,成交额8.05亿元。董秘最新回复投资者: 请问贵司有没有利用ai进行创新药的研发?贵司三期临床的创新药表现好的话,能否提前结束三期?公司会充分结合实际,积极使用新技术,并按计划有序推进创新药的临床进度,有关创新药的进展情况请以公司公告为准。当日关注点交易信息汇总:6月26日主力资金净流出4680.62万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900000477.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0239","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646333302","title":"众生药业:公司会充分结合实际,积极使用新技术","url":"https://stock-news.laohu8.com/highlight/detail?id=2646333302","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646333302?lang=zh_cn&edition=full","pubTime":"2026-06-26 11:34","pubTimestamp":1782444862,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业(002317)06月26日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵司有没有利用ai进行创新药的研发?或者是使用ai加快创新药的研发?贵司三期临床的创新药表现好的话,能否提前结束三期?众生药业回复:感谢您对公司的关注!公司会充分结合实际,积极使用新技术,并按计划有序推进创新药的临床进度,有关创新药的进展情况请以公司公告为准。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600018259.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0188","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644470697","title":"众生药业涨9.99%,开源证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2644470697","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644470697?lang=zh_cn&edition=full","pubTime":"2026-06-18 16:40","pubTimestamp":1781772050,"startTime":"0","endTime":"0","summary":"今日众生药业涨9.99%,收盘报22.9元。2026年4月30日,开源证券研究员余汝意,巢舒然发布了对众生药业的研报《公司信息更新报告:2025年经营业绩稳健提升,创新布局赋能发展》,该研报对众生药业给出“买入”评级。此外,东海证券研究员杜永宏,付婷,华鑫证券研究员胡博新近期也对该股发布了研报,同样给出“买入”评级。众生药业个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800028878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644170386","title":"6月18日众生药业(002317)涨停分析:减肥药、MASH创新药、流感药驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2644170386","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644170386?lang=zh_cn&edition=full","pubTime":"2026-06-18 15:41","pubTimestamp":1781768485,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业6月18日涨停收盘,收盘价22.9元。6月18日众生药业涨停的可能因素有:RAY1225减肥药II期临床数据亮眼,亮相ADA大会并完成III期入组;ZSP1601治疗MASH的IIb期顶线数据积极,疗效显著优于安慰剂;昂拉地韦颗粒获CDE优先审评,儿童流感适应症进展顺利;公司2025年扭亏为盈、2026Q1净利润同比增20.83%,创新药管线加速兑现。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800022267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK1161","159992","002317","BK1574","BK0239","BK0188","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644951744","title":"众生药业(002317)披露使用闲置自有资金进行委托理财的进展公告,6月17日股价下跌4.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644951744","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644951744?lang=zh_cn&edition=full","pubTime":"2026-06-17 22:13","pubTimestamp":1781705597,"startTime":"0","endTime":"0","summary":"截至2026年6月17日收盘,众生药业报收于20.82元,较前一交易日下跌4.71%,最新总市值为176.96亿元。近日,广东众生药业股份有限公司发布《关于使用闲置自有资金进行委托理财的进展公告》。公告显示,公司于2026年6月16日使用控股子公司众生睿创3,000万元闲置自有资金购买东莞银行结构性存款产品,产品期限为71天,起息日为2026年6月18日,到期日为2026年8月28日,预期年化收益率为1.10%至1.70%,产品类型为保本浮动收益型。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700042091.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","002317","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644716552","title":"众生药业:昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2644716552","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644716552?lang=zh_cn&edition=full","pubTime":"2026-06-17 15:21","pubTimestamp":1781680867,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业(002317)06月17日在投资者关系平台上答复投资者关心的问题。投资者提问:已经26年6月中旬了,昂拉地韦片25年销量数据还没有公布,需要讳莫如深吗?还是害怕像新冠特效药那样?众生药业回复:您好!昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药,适用于成人单纯性甲型流感患者的治疗,销售与流感季节性相关。公司正持续推进学术推广与渠道建设,后续将结合流感周期与医保落地效应,稳步推动昂拉地韦片的商业化工作。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700020366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002317","BK0239","BK1574","BK1161","BK0077","06978","159992"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784174768842,"stockEarnings":[{"period":"1week","weight":0.2819},{"period":"1month","weight":0.4769},{"period":"3month","weight":0.7863},{"period":"6month","weight":0.5196},{"period":"1year","weight":1.1042},{"period":"ytd","weight":0.7694}],"compareEarnings":[{"period":"1week","weight":-0.0039},{"period":"1month","weight":-0.0345},{"period":"3month","weight":-0.0246},{"period":"6month","weight":-0.0357},{"period":"1year","weight":0.1286},{"period":"ytd","weight":-0.0033}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广东众生药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"111004人(较上一季度减少2.61%)","perCapita":"6861股","listingDate":"2009-12-11","address":"广东省东莞市石龙镇西湖工业区信息产业园","registeredCapital":"84993万元","survey":" 广东众生药业股份有限公司的主营业务是药品研发、生产和销售。公司的主要产品是昂拉地韦片、来瑞特韦片、复方血栓通系列产品、脑栓通胶囊、复方丹参片、众生丸系列产品、清热祛湿颗粒、羧甲司坦口服溶液(片)、盐酸氨溴索口服溶液、头孢克肟分散片、头孢拉定胶囊、异烟肼片、吡嗪酰胺片、盐酸乙胺丁醇片、利福平胶囊、利巴韦林片、硫糖铝口服混悬液、瑞巴派特片、奥美拉唑肠溶胶囊、盐酸氮䓬斯汀滴眼液、普拉洛芬滴眼液、地夸磷索钠滴眼液、环孢素滴眼液(III)、氯雷他定片、富马酸氯马斯汀口服溶液。","listedPrice":55},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"众生药业(002317)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供众生药业(002317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"众生药业,002317,众生药业股票,众生药业股票老虎,众生药业股票老虎国际,众生药业行情,众生药业股票行情,众生药业股价,众生药业股市,众生药业股票价格,众生药业股票交易,众生药业股票购买,众生药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"众生药业(002317)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供众生药业(002317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}